19 December 2019
Visiongain’s new report the Acne Drugs Market Report 2019-2029: Forecasts by Type (Comedonal, Inflammatory, Cystic, Post-Surgical/wound), by Therapeutic Class(Retinoid, Hormonal Agent, Antibiotic, Combination, Others), by Mode of Administration (Topical, Injectable, Oral) plus analysis of leading companies indicates that the global Acne Drugs market will attain $6.8 billion in revenue by 2029.
Global Acne Drugs market is expected to grow on account of the rising burden of chronic diseases and growing impact of biologics in drug discovery and therapeutics. The market is expected to grow at a healthy CAGR of 4.3% over the projected period.
Acne is a skin disorder that happens when the pores of the skin are obstructed by oil and dead skin cells. Acne mainly impacts adolescents; at least a mild type of this disorder is experienced by over 85% of the population. It happens most frequently on the face, chest, back, shoulders, and neck. Acne similarly affects young males and females, but distinctions exist. Men are more probable to have serious, more durable types of acne than females. In comparison, because of hormonal modifications associated with their menstrual cycle and acne induced by cosmetics, females are more probable to have intermittent acne.
Acne is projected to affect 9.4% of the world's population, making it the world's eighth most common disease. Because of hormonal modifications, it is most prevalent in teenagers and young adults. In 80% of instances, a genetic function is believed to be the main cause. Americans spend an estimated $3 million a year on acne therapy, and 30% depend on OTC products. Many efficient acne treatments, such as antibiotics, benzoyl peroxide, retinoids, and salicylic acid, are available in the market.
Some acne treatments, however, have become controversial. For instance, accutane had severe side effects, including liver damage, birth defects, gastrointestinal illnesses, depression, and suicide, and was eventually withdrawn from the market as a result of a class action suit. While many of the medicines are efficient, these products' complex regimen and side impacts contribute to bad adherence, which undermines therapy achievement. There is space for enhancement in this treatment region as no new products have been on the market in 10 years since the same products have been repurposed by pharmaceutical companies.
Innovation in acne treatment is long overdue but the therapy pipeline looks promising. Current acne treatments are effective, but there are complex regimens and common side effects. Better knowledge of acne pathology leads to fresh, safer, therapy goals being identified, and dermatologists and field scientists are enthusiastic about the pipeline.
.In 2019, North America Acne Drugs market accounted for more than 30% of overall market share. With strong economic growth, changing lifestyle, unhealthy diets and easily availability of acne treatment products, North America acne drugs market is anticipated to retain its position over the forecast period.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.
03 July 2020
Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
03 July 2020
With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.
01 July 2020
The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.